Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 17/20 | 0.81 |
| ▸ | PSEN2 | P49810 | 17/20 | 0.81 |
| ▸ | APH1B | Q8WW43 | 17/20 | 0.81 |
| ▸ | NCSTN | Q92542 | 17/20 | 0.81 |
| ▸ | APH1A | Q96BI3 | 17/20 | 0.81 |
| ▸ | PSENEN | Q9NZ42 | 17/20 | 0.81 |
| ▸ | CCKBR | P32239 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547413 | 0.93 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502669 | 0.93 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502677 | 0.91 | PSEN1 (0.97) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13675304 | 0.84 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13869423 | 0.83 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502668 | 0.82 | PSEN1 (0.97) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13547414 | 0.82 | PSEN1 (0.97) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502739 | 0.80 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502736 | 0.80 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13675303 | 0.79 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7528249-B2 | Cyclic malonamides as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-7390896-B2 | Cyclic malonamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 9/4885APH1B 5/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 5/4885 |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 9/4885APH1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.